These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21873160)

  • 1. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
    Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
    Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Ishikura N; Yorozu K; Kurasawa M; Yanagisawa M; Sugimoto M; Yamamoto K
    Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
    Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
    Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
    Martarelli D; Pompei P; Mazzoni G
    Chemotherapy; 2009; 55(6):425-32. PubMed ID: 19996587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
    Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
    Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
    Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
    Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity.
    Kageyama T; Ohishi M; Miyamoto S; Mizushima H; Iwamoto R; Mekada E
    J Biochem; 2007 Jul; 142(1):95-104. PubMed ID: 17525101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.